Jump to content

JOIN THE DISCUSSION!

Want to join the discussions?

Sign up for a free membership! 

If you are a member already, log in!

(lost your password? reset it here)

99nicu.org 99nicu.org

Leaderboard

  1. Stefan Johansson

    Stefan Johansson

    Administrators


    • Points

      6

    • Content Count

      2,581


  2. MWells

    MWells

    Members


    • Points

      6

    • Content Count

      0


  3. Amy Holmes

    Amy Holmes

    Members


    • Points

      5

    • Content Count

      0


  4. Constance Terrell

    • Points

      3

    • Content Count

      0


Popular Content

Showing content with the highest reputation since 10/21/2013 in Tutorials

  1. Dose & administration Three doses at 24-hour intervals, as intravenous injections over 15 minutes, or by oro-gastric administration: 1st dose: 10 mg/kg 2nd and 3rd dose: 5 mg/kg Indications Closure of the patent ductus arteriosus. Contraindications and special considerations (incl incompatibilities) Contraindications include: duct-dependent cardiovascular malformation active bleeding, including intracranial, gastrointestinal or lung bleeding necrotizing enterocolitis (confirmed or suspected) significant thrombocytopenia or coagulation d
    4 points
  2. Dose & administration Initial dose: 0.05 to 0.1 microgram/kg/min via continuous IV infusion. Titrate to response, then decrease rate to provide the lowest dose while maintaining effect. Maximum dose: 0.4 microgram/kg/min. Higher initial infusion rates do not produce greater effects and are associated with more adverse effects Indications To maintain patency of the ductus arteriosus in congenital heart diseases dependent on shunting for oxygenation Contraindications and special considerations (incl incompatibilities) There are no known contraindications or incompatibili
    4 points
  3. Dose & administration Closure of Ductus Arteriosus: Dose is dependent on age of infant at time of therapy and course includes three doses given IV with 12 to 24 hour intervals between doses (ref 1). Post-natal age at first dose: Less than 48 hours: 1st dose 0.2 mg/kg, followed by 2nd and 3rd doses of 0.1 mg/kg/dose 2-7 days: 0.2 mg/kg/dose >7 days: 1st dose: 0.2 mg/kg, followed by 2nd and 3rd doses of 0.25 mg/kg/dose If the ductus arteriosus closes or is significantly reduced in size after an interval of 48 hours or more from completion of the first course,
    3 points
  4. Dose & administration There are different schools of thought regarding gentamicin dosing in neonates and tertiary dosing references vary in their dosing recommendations. Commonly accepted dosing regimens include both a gestational age based dosing approach as well as birth-weight based dosing approach. Doses range from 4-5mg/kg per dose administered every 24 to 48 hours with lower gestational ages requiring the higher weight based dosing and longer dosing interval than older gestational age infants. The NICE guidelines (UK) recommend 5 mg/kg every 36 hours as the starting dose.
    3 points
  5. Dose & administration Lidocaine should be administered intravenously and can be diluted in dextrose and normal saline solutions. Dose per kg varies according to the duration after the first maintenance dose, and depends on the body temperature when administered: Loading dose – 2 mg/kg over 10 minutes Maintenance dose for normothermic infants: The loading dose is followed by 6 mg/kg/hour over 4 hours, 4 mg/kg/hour over 12 hours, and 2 mg/kg/hour over 12 hours. Hypothermic infants: The loading dose is followed by 7 mg/kg/hour over 3.5 hours, 3.5 mg/kg/hour over 12 h
    2 points
  6. Dose & administration Loading dose 20 mg/kg of caffeine citrate (corresponding to 10 mg/kg of caffeine base), intravenously over 30 minutes. Maintenance dose 5-10 mg/kg once daily, intravenously over 10 minutes or by oral administration, 24 h after the loading dose. A higher maintenance dose can be considered but the possibility of accumulation should be taken into account. Can be discontinued when the infant has been free from significant apneas 5-7 days. Can be diluted in sterile solutions for infusion with glucose 50 mg/ml or sodium chloride 9 mg/ml. Indications Apnea of pr
    2 points
  7. Dose & administration Prevention of iron deficiency: Preterm infants: 2-4 mg/kg/day of elemental iron in divided oral doses; initiate no later than 1 month of age and continued through at least 1 year of age, depending on nutritional context and other iron intake. Maximum of 15 mg/day. Term infants: 1 mg/kg/day of elemental iron orally; may not need to initiate until 4 months of age. Low birth weight infants (<2500 g): 2-3 mg/kg/day of elemental iron in divided oral doses during the first 6 months of life. Treatment of iron deficiency: 4-6 mg/kg/day of eleme
    2 points
  8. Dose & administration Acyclovir is dosed 20mg/kg/dose IV at intervals depending on gestational age. Specifically, Sampson et al (PMID: 24346595) recommend dosing intervals to be 12 hours (q12h) in infants < 30 weeks PMA; 8 hours (q8h) in infants 30 to <36 weeks PMA; and 6 hours (q6h) in infants 36-41 weeks PMA. Administer over one hour in order to prevent adverse effects. For congenital HSV infections, treatment course depends on type of infection. SEM disease is treated for 14 days. Disseminated and CNS infections require a minimum of 21 days of therapy. Asymptomatic in
    2 points
  9. Dose & administration 2-20 mcg/kg/min administered via continuous intravenous infusion, and titrated to desired blood pressure effect. Different doses lead to different patterns of stimulation effects on dopaminergic, beta-1, and alpha receptors (see Pharmacological aspects) Administration of dopamine via large vein is preferred to prevent extravasation Can be administered through intravenous or intraosseous route Avoid bolus administration Dilute vials prior to administration per your local protocols Indications Hypotension: there is no standard definitio
    1 point
  10. Dose & administration 10-15 mg/kg/dose given intravenously per the following interval recommendations, and directed/adjusted by serum concentration measurements: Postmenstrual age (PMA) ≤29 weeks PMA: 0-14 days postnatal age, dosing interval = 18 hours; >14 days postnatal age, dosing interval = 12 hours 30 to 36 weeks PMA: 0-14 days postnatal age, dosing interval = 12 hours; >14 days postnatal age, dosing interval = 8 hours 37 to 44 weeks PMA: 0-7 days postnatal age, dosing interval = 12 hours; >7 days, dosing interval = 8 hours ≥45 weeks PMA: all p
    1 point
  11. Dose & administration The dose depends on gestational age (GA) and postnatal age (PNA): ≤ 34 weeks GA and ≤ 7 days PNA: 50 mg/kg/dose, every 12 hours (q12h). ≤ 34 weeks GA and 8 - 28 days PNA: 75 mg/kg/dose, every 12 hours (q12h). ≥ 35 weeks GA and 0-28 days PNA: 50 mg/kg/dose, every 8 hours (q8h). In the case of meningitis or severe septicemia the doses may be increased twofold. Maximal dose: 400 mg/kg/day IV administration is preferable, as an IV push over 3-5 min. Intraosseous injection may be used if venous access is not available, but intramuscular injec
    1 point
This leaderboard is set to Stockholm/GMT+02:00
×
×
  • Create New...